Polatuzumab vedotin-piiq

(Polivy®)

Polatuzumab vedotin-piiq

Latest News

loading GIF

Drug updated on 4/18/2024

Dosage FormInjection (intravenous; 30 mg/vial, 140 mg/vial)
Drug ClassCD79b-directed antibodies and microtubule inhibitor conjugates
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated in combination with a rituximab product, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for the treatment of adult patients who have previously untreated diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS) or high-grade B-cell lymphoma (HGBL) and who have an International Prognostic Index score of 2 or greater.
  • Indicated in combination with bendamustine and a rituximab product for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified, after at least two prior therapies.

Summary
This AI-generated content is provided without warranty and may be inaccurate or outdated; it should be used only as a research starting point, with no liability accepted for reliance on it. Learn more.

  • Polatuzumab vedotin-piiq (Polivy) is indicated in combination with other drugs for the treatment of adult patients who have previously untreated diffuse large B-cell lymphoma or high-grade B-cell lymphoma and those with relapsed or refractory diffuse large B-cell lymphoma, after at least two prior therapies.
  • Three studies were reviewed to gather information about this drug, focusing on quality of life outcomes, efficacy of salvage treatments, and treatment options for transplant-ineligible patients.
  • According to one study's findings, polatuzumab vedotin showed mixed quality of life outcomes compared to CAR T-cell therapies and traditional salvage chemotherapies. This suggests it may improve lives during progression-free survival periods (up to a utility value score of 0.83), but there is variability during disease progression stages (with scores ranging from 0.39 - 0.71).
  • Another study found no significant difference between CAR T-cell therapies and chemotherapy followed by autologous stem cell transplantation in eligible patients; however, polatuzumab vedotin combined with bendamustine and rituximab demonstrated comparable efficacy in ineligible patients.
  • The third study highlighted the challenge in directly comparing polatuzumab vedotin’s effectiveness due to a lack of randomized controlled trials, which limits understanding against established or newer treatments outside observational studies.
  • Despite these challenges, across all studies, Polivy shows promise, especially within autologous stem cell transplantation (ASCT)-ineligible patient groups, suggesting potential benefits for those with fewer treatment options. However, more robust research is needed, particularly focusing on specific subgroups.